Skip to content

META French logo

Main menu
    • Qui sommes-nous ?
      • Vision, mission et valeurs
      • Diversité, équité & inclusion
      • Nos dirigeants
      • Équipe de direction
      • Conseil d’administration
    • Environnement, social & gouvernance
    • Politiques et positions
    • Fournisseurs
    • Médias
    • Communiqués de presse
    • Aperçu des relations avec les investisseurs
    • Dépôts auprès de la SEC
  • Rejoignez notre équipe

Nous Contacter

Main menu

Organon site directory

  • Organon

    • Brazil
    • Canada  English  ·  French
    • Latin America
    • Mexico
    • USA
  • Organon

    • Austria
    • Belgium  Dutch  ·  English  ·  French
    • Bulgaria
    • Czech Republic
    • Denmark
    • Estonia
    • Finland
    • France
    • Germany
    • Hungary
    • Ireland
    • Italy
    • Latvia
    • Lithuania
    • Luxembourg  English  ·  French
    • Netherlands  Dutch  ·  English
    • Norway
    • Poland
    • Portugal
    • Romania
    • Russia
    • Serbia
    • Slovakia
    • Slovenia
    • Spain
    • Sweden
    • Switzerland  French  ·  German  ·  English
    • Ukraine  Ukrainian  · 
    • United Kingdom
  • Organon

    • Australia
    • Hong Kong, China
    • Indonesia
    • Japan
    • Malaysia
    • New Zealand
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Organon

    • Egypt
    • Israel
    • Jordan
    • KSA
    • Kuwait
    • Lebanon
    • Northwest Africa  French  ·  Arabic  ·  Turkey
    • Oman
    • South Africa
    • Turkey
    • UAE
View all locations and contact information

What can we help you find?

Search for:

Équipe de direction

L’équipe de direction Notre équipe de direction gère la direction stratégique et les opérations de notre entreprise. Grâce à leurs expériences professionnelles et variées, ils guident notre façon de faire et ce que nous représentons.

Photo of Kevin Ali, PDG

Kevin Ali, PDG

Photo of Susanne Fiedler, Directrice Commerciale

Susanne Fiedler, Directrice Commerciale

Photo of Juan Camilo Arjona Ferreira

Juan Camilo Arjona Ferreira, Responsable de recherche et développement et directeur médical

Photo of Joseph Morrissey, Responsable de la fabrication et de l'approvisionnement

Joseph Morrissey, Responsable de la fabrication et de l'approvisionnement

Photo of Vittorio Nisita, Chef des services commerciaux mondiaux

Vittorio Nisita, Chef des services commerciaux mondiaux

Photo of Aaron Falcione, Directeur général des ressources humaines

Aaron Falcione, Directeur général des ressources humaines

Photo of Matthew Walsh, Directeur financier

Matthew Walsh, Directeur financier

Photo of Rachel Stahler, Directrice Générale de l’information

Rachel Stahler, Directrice Générale de l’information

Photo of Tom Merriam

Tom Merriam, Responsable de la stratégie d'entreprise et directeur de cabinet

Photo of Kirke Weaver

Kirke Weaver, Directeur juridique et Secrétaire général

META French logo

Société

  • Qui sommes-nous ?
  • Nos dirigeants
  • Environnement, social & gouvernance

Ressources

  • Ressources pour les patients
  • Relations avec les investisseurs
  • Médias

Nous contacter

  • Informations de contact
  • Global
  • Énoncés prospectifs
  • Politique en matière de cookies
  • Politique de confidentialité
  • Conditions d’utilisation
  • Plan du site
Copyright © 2025 Organon group of companies.Groupe de sociétés Organon Tous droits réservés.

You are leaving Organon.com

Cancel Continue Opens a new window

Forward-looking statement of Organon

This news release of Organon (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2020 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov Opens a new window ).

No Duty to Update

The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.

Decline Accept